1. Open Targets Platform: supporting systematic drug-target identification and prioritisation
- Author
-
Ellen M. McDonagh, Denise Carvalho-Silva, Jeremy Schwartzentruber, Adam Faulconbridge, Asier Gonzalez-Uriarte, Michaela Spitzer, Ian Dunham, Eliseo Papa, Elaine McAuley, David Ochoa, Luca Fumis, Chuang Kee Ong, Andrea Pierleoni, Daniel Suveges, Jarrod Baker, Andrew Hercules, Gareth Peat, Edward Mountjoy, Eirini Petsalaki, Prudence Mutowo, Miguel Carmona, Gautier Koscielny, Miguel Pignatelli, David G. Hulcoop, Olesya Razuvayevskaya, Sandra Machlitt-Northen, Cinzia Malangone, Javier Ferrer, Mohd Anisul Karim, Maya Ghoussaini, Alfredo Miranda, and Arwa Bin Raies
- Subjects
Databases, Factual ,AcademicSubjects/SCI00010 ,Knowledge Bases ,Datasets as Topic ,Antineoplastic Agents ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Drug Discovery ,Genetics ,Humans ,Database Issue ,Molecular Targeted Therapy ,030304 developmental biology ,0303 health sciences ,Internet ,Drug discovery ,business.industry ,Usability ,Drugs, Investigational ,Data science ,Biobank ,Identification (information) ,Key (cryptography) ,The Internet ,User interface ,business ,030217 neurology & neurosurgery ,Software - Abstract
The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.
- Published
- 2020